Nicotinamide Glaucoma Risk became a sharper research question after a large U.S. observational cohort study linked systemic nicotinamide supplementation with lower rates of primary open-angle glaucoma, or POAG, among patients with ocular hypertension. The finding is relevant for glaucoma care, but it should not be read as proof that a supplement prevents disease, and it was not a sports-specific trial.
For athletes, the practical relevance is narrow but real. Ocular hypertension can sit quietly beside high training loads, travel, dehydration, bright-light exposure, and heavy screen use. None of those factors means an athlete has glaucoma. Still, an athlete already followed as an ocular hypertension patient may reasonably ask whether this vitamin B3 signal changes monitoring, supplement discussions, or risk framing. The safest answer is cautious: the data are promising, observational, and not a substitute for an eye-care plan.
What The 2026 OHT Cohort Found
A Large U.S. Data Set
The main study was published online on July 9, 2026, in JAMA Ophthalmology. It evaluated systemic nicotinamide supplementation in patients with ocular hypertension across 67 U.S. health-care organizations from March 2006 through March 2026, according to the PubMed record. The matched study population included 2,920 patients: 1,460 with documented nicotinamide exposure and 1,460 without exposure.
Mean age was about 54 to 55 years, and roughly 58% to 60% of participants were female. Mean follow-up was 3.7 years, with a reported standard deviation of 1.7 years. That time frame is useful because glaucoma risk is not usually judged over days or weeks. It also leaves open the question of what happens over longer horizons, especially for younger ocular hypertension patients who may live with risk monitoring for decades.
Diagnosis Rates In The Matched Groups
During follow-up, 3.5% of patients in the nicotinamide group were diagnosed with POAG, compared with 9.0% of controls. The hazard ratio was 0.34, with a 95% confidence interval of 0.25 to 0.47 and a P value below .001. The absolute risk reduction was 5.5 percentage points, with a 95% confidence interval of 3.8 to 7.3 percentage points.
Those numbers are clinically interesting, but the design matters. This was not a randomized trial. Treatment choice, documentation patterns, supplement access, health behavior, and clinician follow-up could have differed between groups even after matching. Observational studies can detect associations; they cannot fully prove that the exposure caused the difference in outcome.
Nicotinamide Glaucoma Risk And Study Design
Nicotinamide Glaucoma Risk In A Matched Cohort
The Nicotinamide Glaucoma Risk signal came from a population selected to reduce some obvious sources of bias. The cohort excluded patients with prior POAG, prior glaucoma treatment with medications or laser, or prior laser trabeculoplasty. Exposure was defined as documented systemic nicotinamide supplementation. Controls with any history of niacin use were excluded.
That exclusion structure helps focus the analysis on patients with ocular hypertension before glaucoma diagnosis or treatment. It also limits how far the result can be stretched. The findings do not tell us whether nicotinamide helps people who already have established glaucoma, whether it changes visual field outcomes in athletes, or whether it is safe and useful at every possible dose. The research points to a risk association in a defined health-record population, not a universal recommendation.
Why Ocular Hypertension Is A Specific Starting Point
Ocular hypertension is an elevated eye-pressure state without confirmed glaucomatous optic nerve damage or visual field loss. Many people with ocular hypertension do not develop POAG during short or intermediate follow-up, while others do. Risk estimation often depends on age, pressure level, optic nerve appearance, corneal thickness, visual field testing, and family or demographic factors. For a deeper risk-framing discussion, related site coverage on glaucoma suspect monitoring addresses how monitoring can be stratified without overstating certainty.
Athletes with ocular hypertension face the same central issue as non-athletes: preserving vision through measured follow-up. Sport adds performance context, not a separate diagnosis. Peripheral vision, contrast sensitivity, reaction timing, and confidence under bright light can matter in play, but the 2026 cohort did not test sport performance or return-to-play outcomes.
Signals Beyond Diagnosis
Treatment Initiation And Laser Procedures
The cohort also reported differences in progression to first-line topical intraocular pressure-lowering therapy. Such therapy was initiated in 13.6% of the nicotinamide group and 21.2% of controls, with a hazard ratio of 0.57 and a 95% confidence interval of 0.48 to 0.68. Laser trabeculoplasty occurred in 0.8% of nicotinamide users and 1.9% of non-users, with a hazard ratio of 0.38 and a 95% confidence interval of 0.19 to 0.74.
These secondary signals are consistent with the diagnosis findings, yet they also depend on clinical decision-making. Starting drops or recommending laser is influenced by pressure, optic nerve assessment, test reliability, patient preference, medication tolerance, access, and clinician judgment. A lower treatment-initiation rate may reflect lower perceived risk, but it may also reflect patterns not fully captured in electronic health records.
Related Vitamin B3 Evidence
Related U.S. NHANES 2005-2008 cross-sectional data found that higher daily niacin intake, another form of vitamin B3, was associated with lower odds of glaucoma. In that analysis, people in the third or fourth quartiles of niacin intake, at roughly 21 mg/day or higher, had significantly lower odds in adjusted models; the fourth quartile odds ratio was about 0.48 for fundus-imaged glaucoma, as reported in the NHANES analysis. Cross-sectional data cannot establish timing, so they are best read as supportive background rather than confirmation.
Other related evidence in the research record includes a 2019 study reporting that people with POAG in Singapore and French cohorts had about 30% to 33% lower plasma nicotinamide concentrations than age- and sex-matched controls. A systematic review published in August 2026 described preliminary signals for nicotinamide- or NAD-targeted strategies, including short-term biological and electrophysiologic benefits, but judged the evidence insufficient for routine high-dose use in standard practice. Larger and longer randomized trials remain the cleaner test.
How Athletes Should Read The Evidence
Not A Performance Supplement Claim
No sport-specific outcome was tested in the July 2026 cohort. It did not measure batting vision, ball tracking, reaction time, glare recovery, concussion history, or competition results. For that reason, athletes should not treat the finding as a performance-enhancement claim. The research question was POAG development in ocular hypertension patients, not visual performance in training or competition.
The athlete-relevant lesson is about risk literacy. A player, runner, cyclist, or combat-sport athlete with ocular hypertension should know that supplements can interact with broader health status and medical supervision. Even when a nutrient is familiar, dose, formulation, liver status, medication history, pregnancy status, and other personal factors can matter. The study supports a conversation with an eye-care clinician; it does not support self-directed high-dose supplementation as a proven prevention strategy.
Monitoring Still Carries The Workload
For sports vision science, glaucoma risk is not just about central sharpness on an eye chart. Peripheral field loss, contrast changes, and optic nerve damage can affect safe participation long before an athlete notices a problem. Yet the evidence base for nicotinamide does not replace intraocular pressure checks, optic nerve imaging, visual field testing, and follow-up intervals set by clinicians.
Readers who track related vision and health science coverage across the same network can find broader applied-science reporting at Mengo Industries. In glaucoma care, though, the actionable point stays clinical: documented ocular hypertension deserves structured follow-up, and research signals should be weighed against individual risk rather than used as blanket advice.
Nicotinamide Glaucoma Risk For Sports Vision Decisions
For now, Nicotinamide Glaucoma Risk is best understood as a promising association from a large observational cohort, supported by related but not definitive vitamin B3 evidence. The scale of the U.S. data set gives the signal weight, while the non-randomized design keeps the interpretation restrained.
For athletes, the message is not to chase a supplement trend. The message is to ask better questions during eye visits: Am I being monitored as ocular hypertension, glaucoma suspect, or diagnosed POAG? What tests are being used to judge change? Would any supplement discussion fit my medical history? What evidence would change my care plan?
Those questions align sport demands with evidence-based glaucoma care. Nicotinamide may become more relevant if longer randomized trials confirm benefit, clarify dosing, and define safety. As of October 11, 2026, the evidence supports interest and clinician-guided discussion, not routine unsupervised use.